← SynDRA
DEUCRAVACITINIB
SynDRA canonical compound SYN0039867 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | TYK2 |
|---|
| Mechanism of action | tyrosine kinase inhibitor |
|---|
| Indication | crohn's disease |
|---|
| Disease area | gastroenterology |
|---|
All known targets
Mechanisms of action (all sources)
- TYK2 NEGATIVE ALLOSTERIC MODULATOR
- Tyrosine-protein kinase TYK2 negative allosteric modulator
- BMPR2 INHIBITOR
- JAK1 INHIBITOR
- TYK2 INHIBITOR
- tyrosine kinase inhibitor
Drug classes
- Dermatologic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Tyrosine Kinase 2 Inhibitor
- Tyrosine Kinase 2 Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- BMS-986165
- sotyktu
- 6-CYCLOPROPANEAMIDO-4-{[2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL]AMINO}-N-(?H?)METHYLPYRIDAZINE-3-CARBOXAMIDE
- DEUCRAVACITINIB (BMS-986165)
- Sotyktu
- TYK2-IN-4
- bms 986165
- N0A21N6RAU
- RefChem:58358
- Tyk2-IN-4
- BMS986165
- Deucravacitinib [USAN]
- MFCD31715455
- Tyk2-IN-4(BMS986165)
- Sotyktu (TN)
- UNII-N0A21N6RAU
- Deucravacitinib (JAN/USAN)
- DEUCRAVACITINIB [INN]
- DEUCRAVACITINIB [JAN]
- orb1308545
- DEUCRAVACITINIB [WHO-DD]
- SCHEMBL20520348
- SCHEMBL29424395
- Deucravacitinib(BMS986165)?
- GTPL10432
- Deucravacitinib (BMS-986165)
- C20H22N8O3
- GLXC-20380
- SMSSF-0676928
- EX-A3154
- JPC39227
- BDBM50507816
- NSC825520
- s8879
- WHO 11342
- AKOS040741395
- AT18623
- EBC-225024
Look up DEUCRAVACITINIB in the interactive SynDRA portal →